<DOC>
	<DOC>NCT02679755</DOC>
	<brief_summary>A study of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone receptor-positive, her2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate.</brief_summary>
	<brief_title>Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer</brief_title>
	<detailed_description>To provide access to palbociclib to post-menopausal patients with hormone receptor-positive [HR(+)], HER2-negative [HER2(-)] ABC who are deemed appropriate for letrozole therapy.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Postmenopausal women (&gt;=18 years of age) with proven diagnosis of advanced carcinoma of the breast (ER(+) and/or PgR(+) and HER2()) who are appropriate for letrozole therapy (in the firstline advanced/metastatic disease setting). Eastern Cooperative Oncology Group (ECOG) performance status 02. Adequate bone marrow, liver, and renal function. Prior treatment with any CDK inhibitor . QTc &gt;480 msec; history of QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes. High cardiovascular risk, including, but not limited to myocardial infarction, severe/unstable angina, severe cardiac dysrhythmias, and symptomatic pulmonary embolism in the past 6 months of enrollment.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hormone receptor positive advanced breast cancer</keyword>
</DOC>